Bronchodilator effect of delta1‐tetrahydrocannabinol.

Hartley, J P; Nogrady, S G; Seaton, Anthony

doi:10.1111/j.1365-2125.1978.tb01667.x

Cited by 43 publications

(19 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bronchodilation induced by smoked marijuana and oral THC was also documented in subjects with mild to moderate asthma and in asthmatic patients with methacholine-or exercise-induced bronchoconstriction (Tashkin et al, 1974(Tashkin et al, , 1975. Bronchodilation without side effects was observed in asthmatic patients after a low dose (0.2 mg) of nebulized THC (Williams et al, 1976;Hartley et al, 1978). In contrast, aerosols containing larger doses of THC (5-20 mg) caused paradoxical bronchoconstriction attributed to local irritation .…”

Section: Cardiovascular and Respiratory Disordersmentioning

confidence: 86%

The Endocannabinoid System as an Emerging Target of Pharmacotherapy

2006

View full text Add to dashboard Cite

Section: Cardiovascular and Respiratory Disordersmentioning

confidence: 86%

The Endocannabinoid System as an Emerging Target of Pharmacotherapy

2006

View full text Add to dashboard Cite

“…Pure ⌬ 9 -THC produces bronchodilation in asthmatic patients (329) and may have therapeutic value in asthma also by virtue of its anti-inflammatory effects (933). Indeed, in allergic airway disease induced in mice by aerosolized ovalbumin, pretreatment with ⌬ 9 -THC inhibits the expression of T-cell cytokines elicited by ovalbumin in the lungs and the associated inflammatory response (389).…”

Section: Asthmamentioning

confidence: 99%

From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology

Ligresti¹,

Petrocellis²,

Marzo³

2016

Physiological Reviews

368

337

View full text Add to dashboard Cite

Apart from having been used and misused for at least four millennia for, among others, recreational and medicinal purposes, the cannabis plant and its most peculiar chemical components, the plant cannabinoids (phytocannabinoids), have the merit to have led humanity to discover one of the most intriguing and pleiotropic endogenous signaling systems, the endocannabinoid system (ECS). This review article aims to describe and critically discuss, in the most comprehensive possible manner, the multifaceted aspects of 1) the pharmacology and potential impact on mammalian physiology of all major phytocannabinoids, and not only of the most famous one ⌬ 9 -tetrahydrocannabinol, and 2) the adaptive prohomeostatic physiological, or maladaptive pathological, roles of the ECS in mammalian cells, tissues, and organs. In doing so, we have respected the chronological order of the milestones of the millennial route from medicinal/recreational cannabis to the ECS and beyond, as it is now clear that some of the early steps in this long path, which were originally neglected, are becoming important again. The emerging picture is rather complex, but still supports the belief that more important discoveries on human physiology, and new therapies, might come in the future from new knowledge in this field.

show abstract

“…Despite its present classification as a controlled substance in the majority of the Western world, reports on the use of herbal preparations of the plant for recreational and self-medication purposes have implicated the effectiveness of extracts of the plant in the treatment of a variety of ailments, including asthma and cough (O'Shaughnessy, 1842;van Hoozen and Cross, 1997;Iversen, 2000). Botanical preparations of the cannabis plant and certain plant-derived cannabinoids have been evaluated for their bronchodilator (Vachon et al,1973;Tashkin et al, 1974Tashkin et al, , 1975Tashkin et al, , 1977Williams et al, 1976;Hartley et al, 1978;Grassin-Delyle et al, 2014), anti-inflammatory (Jan et al, 2003), and antitussive (Gordon et al, 1976) activity in subjects with asthma and in experimental animals. However, because of local irritation of the airways caused by constituents of the cannabis smoke, the poor bioavailability of the plant components following oral administration, and the intoxication caused by D chromen-1-ol], the major pharmacologically active component of cannabis, the medicinal use of cannabis for treatment of inflammatory and respiratory diseases has been hampered Tashkin et al, 1977).…”

Section: Introductionmentioning

confidence: 99%

The Effect of Phytocannabinoids on Airway Hyper-Responsiveness, Airway Inflammation, and Cough

Makwana

Venkatasamy

Spina

et al. 2015

J Pharmacol Exp Ther

View full text Add to dashboard Cite

Cannabis has been demonstrated to have bronchodilator, antiinflammatory, and antitussive activity in the airways, but information on the active cannabinoids, their receptors, and the mechanisms for these effects is limited. We compared the effects of D 9-tetrahydrocannabinol, cannabidiol, cannabigerol, cannabichromene, cannabidiolic acid, and tetrahydrocannabivarin on contractions of the guinea pig-isolated trachea and bronchoconstriction induced by nerve stimulation or methacholine in anesthetized guinea pigs following exposure to saline or the proinflammatory cytokine, tumor necrosis factor a (TNF-a). CP55940 (2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl) phenol), a synthetic cannabinoid agonist, was also investigated in vitro. The cannabinoids were also evaluated on TNF-aand lipopolysaccharide-induced leukocyte infiltration into the lungs and citric acid-induced cough responses in guinea pigs. TNF-a, but not saline, augmented tracheal contractility and bronchoconstriction induced by nerve stimulation, but not methacholine. D 9 -Tetrahydrocannabinol and CP55940 reduced TNF-a2enhanced nerve-evoked contractions in vitro to the magnitude of saline-incubated trachea. This effect was antagonized by the cannabinoid 1 (CB 1 ) and CB 2 receptor antagonists AM251 [N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-caroxamide] and JTE907 [N-(1,3-benzodioxol-5-ylmethyl)-1,2-dihydro-7-methoxy-2-oxo-8-(pentyloxy)-3-quinolinecarboxamide], respectively. Tetrahydrocannabivarin partially inhibited the TNF-a2enhanced nerve-evoked contractions, whereas the other cannabinoids were without effect. The effect of cannabidiol and D 9-tetrahydrocannabinol together did not differ from that of the latter alone. Only -THC demonstrated effects on airway hyper-responsiveness, anti-inflammatory activity, and antitussive activity in the airways.

show abstract

Bronchodilator effect of delta1‐tetrahydrocannabinol.

Cited by 43 publications

References 10 publications

The Endocannabinoid System as an Emerging Target of Pharmacotherapy

The Endocannabinoid System as an Emerging Target of Pharmacotherapy

From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology

The Effect of Phytocannabinoids on Airway Hyper-Responsiveness, Airway Inflammation, and Cough

Contact Info

Product

Resources

About